Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To evaluate antianginal and antiischemic efficiency of nebivolol in patients with stable angina pectoris.

Material and methods. 100 patients with ischemic heart disease showing stable exertional angina pectoris and having no contraindications to beta-blockers were studied. After 5-7 days of control period 50 randomly selected patients began to take nebivolol in initial dose of 5mg once daily and 50 patients started to take metoprolol in initial dose of 50 mg twice daily. Duration of treatment was 8 weeks. Efficiency of treatment was assessed according to the results of control treadmill assessment and control daily ECG monitoring.

Results. 56-day therapy with nebivolol at a dose of 7,5 mg per day results in increase in duration of treadmill test before angina or ST depression (p<0.05). Antianginal and antiischemic effect of nebivolol 7.5 mg once daily is rather similar with that of metoprolol in average daily dose of 175 mg. Nebivolol compared to metoprolol significantly (p<0.05) more effectively reduces the number of silent myocardial ischemia.

Conclusion. Nebivolol is an efficient antianginal and antiischemic drug for patients with stable exertional angina pectoris.

About the Authors

Y. V. Gavrilov
Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Chair of Faculty therapy №1

V. A. Sulimov
Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Chair of Faculty therapy №1

V. I. Makolkin
Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Chair of Faculty therapy №1


1. Лечение стабильной стенокардии. Рекомендации специальной комиссии Европейского общества кардиологов. РМЖ 2006; 14(20):1402-6.

2. Чазов Е.И. Проблема лечения больных ишемической болезнью сердца. Тер арх 2000;(9):5–9.

3. Метелица В.И. Справочник по клинической фармакологии сердечно–сосудистых лекарственных средств. М.: БИНОМ – СПб.: Невский диалект, 2002.

4. Болезни сердца и сосудов. Руководство для врачей. Под редакцией Е. И. Чазова. М.: Медицина. 1992., т. 1.

5. Кондратьев В.В., Бочкарева Е.В., Кокурина Е.В. Безболевая ишемия миокарда. Современное состояние проблемы и клинически значимые аспекты её развития. Механизмы формирования безболевой ишемии миокарда. Кардиология 1997;(2):90–7.

6. Goldstein S. Beta-blocking drugs and coronary heart disease. Cardiovasc Drugs Ther 1997;11:219-25.

7. Van Nueten L., Walgraeve H. Pharmacodynamic effects of Nebivolol. JRF Clinical Research Report on R67555. January 1995.

8. Cheymol G., Woestenborghs R., Snoeck E., et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997;51:493-8.

9. Cherchi A. et al. Antianginal and antiischemic activity of nebivolol in stable angina of effort. Drug Invest 1991;3(Suppl 1):86-98.

10. Ruf G, Trenk D, Jahnchen E, Roskamm H. Determination of the anti￾ischemic activity of nebivolol in comparison with atenolol. Int J Cardiol 1994;43:279-85.

11. Ulvenstam G. A single blind dose-ranging study of the effect of nebivolol in patients with angina pectoris. Drug Invest 1991;3( Suppl. 1):199-200.

12. Маколкин В.И. Небиволол - представитель нового поколения b- адреноблокатров. Кардиология 2000;(12):69-71.

13. Манухина Е.Б., Малышев И.Ю., Бувальцев В.И. Эндотелиальная дисфункция и артериальная гипертензия: механизмы и пути коррекции. Кардиоваск тер профилакт 2003;2(4):26-30.

14. Бувальцев В.И. Дисфункция эндотелия как новая концепция профилактики и лечения сердечно-сосудистых заболеваний. Международный медицинский журнал 2001;(3).

15. Затейщиков Д.А. Метопролол. Применение в кардиологии. Кардиология 1997;(5):92–5.

For citation:

Gavrilov Y.V., Sulimov V.A., Makolkin V.I. NEBIVOLOL IN TREATMENT OF STABLE EXERTIONAL ANGINA PECTORIS. Rational Pharmacotherapy in Cardiology. 2007;3(2):11-15. (In Russ.)

Views: 3389

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)